Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
William G. Rice
|
| gptkbp:country |
gptkb:Canada
gptkb:United_States |
| gptkbp:focus |
oncology
hematologic malignancies |
| gptkbp:formerName |
Lorus Therapeutics
|
| gptkbp:foundedYear |
1986
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_USA
gptkb:Toronto,_Ontario,_Canada |
| https://www.w3.org/2000/01/rdf-schema#label |
Aptose Biosciences
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:products |
APTO-253
CG-806 |
| gptkbp:publiclyTraded |
true
|
| gptkbp:researchInterest |
precision medicine
small molecule therapeutics |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
APTO
|
| gptkbp:website |
https://www.aptose.com/
|
| gptkbp:bfsParent |
gptkb:Sorrento_Mesa
|
| gptkbp:bfsLayer |
8
|